Drug Database
Back to search

Switzerland· 63283001

Triumeq, Filmtabletten

A lamivudine, abacavir and dolutegravir product containing dolutegravirum, abacavirum, lamivudinum, registered in Switzerland by ViiV Healthcare GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AR13

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedTriumeq, FilmtablettenATCJ05AR13REGISTER NO.63283001PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dolutegravirum, abacavirum, lamivudinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lamivudine, abacavir and dolutegravir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR13 (lamivudine, abacavir and dolutegravir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 8 of them publish a price we can compare per daily dose
Search lamivudine, abacavir and dolutegravir products by name

Lamivudine, abacavir and dolutegravir · ATC J05AR13

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
dolutegravirum, abacavirum, lamivudinum
Manufacturer
ViiV Healthcare GmbH
Country
Switzerland (CH)
ATC code
J05AR13
ATC class
Lamivudine, abacavir and dolutegravir
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680632830010
    30 Stk
    CHF 992.7

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for lamivudine, abacavir and dolutegravir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lamivudine, abacavir and dolutegravir against other medicinesHow interaction checks work

Lamivudine, abacavir and dolutegravir · interactions on record

2 records

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lamivudine, abacavir and dolutegravir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine, abacavir and dolutegravir products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Iceland · Triumeq
  • Liechtenstein · Triumeq
  • Malta · Dolutegravir/Abacavir/Lamivudine Pharos
  • Norway · Triumeq
  • Portugal · Dolutegravir/Abacavir/Lamivudine Pharos

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ae7c06e1-bf06-4ff5-a299-c8ef7d7d62cf
GET /v1/drugs/ae7c06e1-bf06-4ff5-a299-c8ef7d7d62cf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "dolutegravirum 50 mg + abacavirum 600 mg + lamivudinum 300 mg",
  "valid_from": "2015-03-01",
  "limitations": "[{\"description\":\"Zur Behandlung von Infektionen mit dem humanen Immundefizienz-Virus (HIV) bei Erwachsenen, Jugendlichen und Kindern ab 25 kg, welche nicht antiretroviral vorbehandelt sind oder bei denen HIV keine dokumentierte oder klinisch vermutete Resistenz gegen einen der drei antiretroviralen Wirkstoffe von Triumeq aufweist.<br>\\n<br>\\n\\n\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-06-01\"}]",
  "galenic_form": "Filmtabl",
  "therapeutic_area": null,
  "sl_inclusion_date": "2015-03-01",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about lamivudine, abacavir and dolutegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console